CGON Stock — CG Oncology Inc.: Cash, EV, Pipeline

Share price

$74.62

Market cap

$6,614.3M

Cash

$1,028.3M

Enterprise value

$5,589.0M

Balance sheet

Cash	$1,028.3M
Debt	$3.0M
Net cash	$1,025.3M
Enterprise value	$5,589.0M
Basic shares	88.3M shares
Fully diluted shares	103.4M shares
Fully diluted market cap	$7,715.8M
Cash per share	$11.65

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CGON daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	Cretostimogene Grenadenorepvec	Phase 3	Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer	—
May 12 - Jun 23	Cretostimogene Grenadenorepvec	Phase 2	High-Risk Non-Muscle-Invasive Bladder Cancer	—
Jul 28 - Sep 8	Cretostimogene Grenadenorepvec	Phase 3	Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

cretostimogene

Phase 3 · Active Modality: oncolytic immunotherapy

Aliases cretostimogene grenadenorepvec

Indications

high-risk BCG-unresponsive NMIBC with CIS (BOND-003 Cohort C) (Phase 3)
intermediate-risk NMIBC, adjuvant post-TURBT (PIVOT-006) (Phase 3)
high-risk BCG-naive NMIBC (CORE-008 Cohort A) (Phase 2)
high-risk BCG-exposed NMIBC (Phase 2)
high-risk BCG-unresponsive NMIBC, combination with pembrolizumab (CORE-001) (Phase 2)

Status note Only product candidate; FDA Breakthrough Therapy designation noted. PIVOT-006 enrollment completed Q3 2025. Designed as potential backbone therapy for bladder cancer.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Cretostimogene Grenadenorepvec
Lead indication	Non Muscle Invasive Bladder Cancer
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06111235	Phase 3	Active, not recruiting	Sponsor	CG Oncology, Inc.	—	Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer	—
NCT04452591	Phase 3	Active, not recruiting	Sponsor	CG Oncology, Inc.	—	Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer	—
NCT06567743	Phase 2	Recruiting	Sponsor	CG Oncology, Inc.	—	High-Risk Non-Muscle-Invasive Bladder Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for CG Oncology, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	8,514,590	+1,529,782	5.16%	2026-08-14
Logos Global Management	1,000,000	+425,000	3.06%	2026-08-14
OrbiMed Advisors	972,800	+24,533	1.31%	2026-08-14
ADAR1 Capital Management	118,664	-67,035	0.40%	2026-08-14
Braidwell LP	0	-984,783	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CGON — CG Oncology Inc.